PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

Cashing in on the exuberance around Karuna Therapeutics and its potential blockbuster CNS drug, PureTech has sold a chunk of the biotech’s shares to Goldman Sachs for $200 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

Sol­id Tu­mors: The Next Fron­tier of Can­cer Im­muno-ther­a­py

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy